AU2009241645B2 - Products and methods for stimulating an immune response - Google Patents

Products and methods for stimulating an immune response Download PDF

Info

Publication number
AU2009241645B2
AU2009241645B2 AU2009241645A AU2009241645A AU2009241645B2 AU 2009241645 B2 AU2009241645 B2 AU 2009241645B2 AU 2009241645 A AU2009241645 A AU 2009241645A AU 2009241645 A AU2009241645 A AU 2009241645A AU 2009241645 B2 AU2009241645 B2 AU 2009241645B2
Authority
AU
Australia
Prior art keywords
antigen
cells
cell
hel
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009241645A
Other languages
English (en)
Other versions
AU2009241645A1 (en
Inventor
Patricia Barral
Facundo Batista
Vincenzo Cerundolo
Julia Eckl-Dorna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blink Therapeutics Ltd
Original Assignee
University of Oxford
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, Cancer Research Technology Ltd filed Critical University of Oxford
Publication of AU2009241645A1 publication Critical patent/AU2009241645A1/en
Assigned to BLINK THERAPEUTICS LIMITED reassignment BLINK THERAPEUTICS LIMITED Request for Assignment Assignors: CANCER RESEARCH TECHNOLOGY LIMITED, THE CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD
Application granted granted Critical
Publication of AU2009241645B2 publication Critical patent/AU2009241645B2/en
Priority to AU2014250632A priority Critical patent/AU2014250632B2/en
Priority to AU2014250631A priority patent/AU2014250631B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2009241645A 2008-05-02 2009-05-05 Products and methods for stimulating an immune response Ceased AU2009241645B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2014250632A AU2014250632B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response
AU2014250631A AU2014250631B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4981408P 2008-05-02 2008-05-02
US61/049,814 2008-05-02
PCT/GB2009/001111 WO2009133378A2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2014250632A Division AU2014250632B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response
AU2014250631A Division AU2014250631B2 (en) 2008-05-02 2014-10-15 Products and methods for stimulating an immune response

Publications (2)

Publication Number Publication Date
AU2009241645A1 AU2009241645A1 (en) 2009-11-05
AU2009241645B2 true AU2009241645B2 (en) 2014-07-17

Family

ID=40888253

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009241645A Ceased AU2009241645B2 (en) 2008-05-02 2009-05-05 Products and methods for stimulating an immune response

Country Status (8)

Country Link
US (1) US20110280930A1 (enExample)
EP (3) EP2288381A2 (enExample)
JP (3) JP5721620B2 (enExample)
CN (1) CN102170903B (enExample)
AU (1) AU2009241645B2 (enExample)
CA (1) CA2723226A1 (enExample)
ES (1) ES2570973T3 (enExample)
WO (1) WO2009133378A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2288381A2 (en) * 2008-05-02 2011-03-02 Cancer Research Technology Limited Products and methods for stimulating an immune response
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
CN107115314B (zh) 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
WO2014133106A1 (ja) * 2013-02-27 2014-09-04 独立行政法人理化学研究所 アレルギー疾患治療薬
GB2514591A (en) 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
WO2015084677A1 (en) * 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
WO2015143295A2 (en) 2014-03-20 2015-09-24 The Regents Of The University Of California Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
AU2015269412B2 (en) * 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11150242B2 (en) * 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
AU2016277471A1 (en) * 2015-06-10 2018-01-04 Astrid TSCHIERSCH-PFREUNDSCHUH Means and methods for treatment of B-cell malignancies
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
NL2017204B1 (en) * 2016-06-08 2017-12-18 Kei International Ltd Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample
WO2017211314A1 (en) 2016-06-08 2017-12-14 Kei International Limited Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN110418651A (zh) 2016-08-02 2019-11-05 哈佛学院院长等 用于调节免疫应答的生物材料
CN110114468A (zh) * 2016-08-17 2019-08-09 奥比思健康解决方案有限责任公司 靶向肿瘤的珠载体及其使用方法
AU2018316253A1 (en) * 2017-08-10 2020-01-16 Dana-Farber Cancer Institute, Inc. LMP1-expressing cells and methods of use thereof
NL2021443B1 (en) 2018-08-08 2020-02-20 Kei International Ltd Synthetic antigens for tuberculosis detection
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP3650466A1 (en) * 2018-11-12 2020-05-13 Consejo Superior De Investigaciones Científicas In vitro production of high affinity monoclonal antibodies
CN111229023B (zh) * 2018-11-29 2022-01-28 内蒙古东盛硅藻土科技创新产业园有限公司 一种化学降解添加剂
JP2022514568A (ja) 2018-12-17 2022-02-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
CN112300987B (zh) * 2020-10-16 2022-04-29 中国农业大学 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用
CN116286631A (zh) * 2023-02-15 2023-06-23 上海长征医院 一种利用CD79b单克隆抗体诱导构建B细胞免疫无能模型及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092607A1 (en) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
ES2092560T5 (es) 1989-12-22 2004-09-16 Mikrogen Molekularbiologische Entwicklungs-Gmbh Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FI933580L (fi) 1991-02-15 1993-10-13 Uab Research Foundation Strukturgen av pneumokockprotein
US6113914A (en) 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
ES2194010T3 (es) 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
CA2196311A1 (en) 1994-08-19 1996-02-29 David H. Sachs Genetically engineered swine cells
AU2002327338A1 (en) 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
DE10164309A1 (de) * 2001-12-28 2003-07-10 Fraunhofer Ges Forschung Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle
WO2004016283A2 (en) * 2002-08-14 2004-02-26 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP2008504216A (ja) * 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
EP1767216B1 (en) 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome
AU2005259685B2 (en) 2004-07-07 2010-04-08 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
ES2625905T3 (es) * 2004-10-01 2017-07-20 Midatech Ltd. Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores
BRPI0617687A2 (pt) 2005-10-25 2011-08-02 Ludwig Inst Cancer Res composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica
US20070231344A1 (en) 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
WO2007051004A2 (en) 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP2288381A2 (en) * 2008-05-02 2011-03-02 Cancer Research Technology Limited Products and methods for stimulating an immune response
JP5782775B2 (ja) 2011-03-29 2015-09-24 ソニー株式会社 情報表示装置および情報表示方法、並びにプログラム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092607A1 (en) * 2005-03-02 2006-09-08 The Secretary Of State For Defence Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIDARD, L. et al., ' Analysis of MHC Class II Presentation of Particulate Antigens by B Lymphocytes', The Journal of Immunology, 1996, Vol 156, pages 2809-2818 *

Also Published As

Publication number Publication date
EP2711020A1 (en) 2014-03-26
EP2711021B1 (en) 2016-03-09
CA2723226A1 (en) 2009-05-11
JP5721620B2 (ja) 2015-05-20
HK1190942A1 (en) 2014-07-18
WO2009133378A3 (en) 2009-12-23
JP2011519847A (ja) 2011-07-14
HK1191548A1 (en) 2014-08-01
EP2288381A2 (en) 2011-03-02
JP2015028023A (ja) 2015-02-12
EP2711021A1 (en) 2014-03-26
US20110280930A1 (en) 2011-11-17
JP2015038066A (ja) 2015-02-26
HK1161542A1 (zh) 2012-07-27
CN102170903B (zh) 2016-04-06
EP2711020B1 (en) 2016-08-10
ES2570973T3 (es) 2016-05-23
AU2009241645A1 (en) 2009-11-05
WO2009133378A2 (en) 2009-11-05
CN102170903A (zh) 2011-08-31
JP5853068B2 (ja) 2016-02-09

Similar Documents

Publication Publication Date Title
EP2711021B1 (en) Products and methods for stimulating an immune response
Pedersen et al. Vaccine adjuvants differentially affect kinetics of antibody and germinal center responses
US12246097B2 (en) Nanoparticle vaccine adjuvant and methods of use thereof
US20110293658A1 (en) Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
US12168051B2 (en) Methods and compositions for stimulating immune response
US20120328660A1 (en) Immunogenic compositions useful in provoking an integrated response to tumor antigens
EP1487477A2 (en) Methods of using flt3-ligand in immunization protocols
AU2014250631B2 (en) Products and methods for stimulating an immune response
EP2651435B1 (en) Method for suppressing an immune response
HK1190942B (en) Products and methods for stimulating an immune response
HK1191548B (en) Products and methods for stimulating an immune response
AU2016240410A1 (en) Pain treatment
HK1161542B (en) Products and methods for stimulating an immune response
US12527862B2 (en) Bactericidal/permeability increasing protein for use in a method of immunization, preferably as an adjuvant in a method of vaccination
WO2023114570A1 (en) Compositions and methods for long-lasting germinal center responses to a priming immunization

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BLINK THERAPEUTICS LIMITED

Free format text: FORMER APPLICANT(S): CANCER RESEARCH TECHNOLOGY LIMITED; THE CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired